Eli Lilly and Co (XSGO:LLYCL) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSGO:LLYCL Eli Lilly and Co XSGO:LLYCL
73 GF Score
Price CLP1,104,400.00
GF Value CLP1,439,146.26
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co  (XSGO:LLYCL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 31.27 29.92

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.11 23.65 30.04 27.42 31.81

XSGO:LLYCL vs JNJ, ABBV, MRK: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.


XSGO:LLYCL
73GF Score
Eli Lilly and Co XSGO:LLYCL
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=23161.44/333.9520*333.9520
=23,161.440

Current CPI (Jun. 2026) = 333.9520.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3,237.212 241.428 4,477.830
201612 3,481.581 241.432 4,815.770
201703 3,244.684 243.801 4,444.480
201706 3,660.184 244.955 4,990.001
201709 3,445.402 246.819 4,661.711
201712 3,548.060 246.524 4,806.354
201803 2,846.476 249.554 3,809.141
201806 3,370.897 251.989 4,467.329
201809 3,425.923 252.439 4,532.160
201812 3,626.324 251.233 4,820.299
201903 3,451.542 254.202 4,534.383
201906 4,169.813 256.143 5,436.484
201909 4,210.924 256.759 5,476.912
201912 5,046.219 256.974 6,557.842
202003 5,171.564 258.115 6,691.026
202006 4,970.294 257.797 6,438.553
202009 4,915.873 260.280 6,307.306
202012 6,199.406 260.474 7,948.218
202103 5,403.242 264.877 6,812.307
202106 5,307.457 271.696 6,523.599
202109 5,741.208 274.310 6,989.493
202112 7,268.374 278.802 8,706.136
202203 6,962.896 287.504 8,087.794
202206 6,064.204 296.311 6,834.552
202209 7,108.489 296.808 7,998.080
202212 7,025.918 296.797 7,905.469
202303 6,247.934 301.836 6,912.728
202306 7,372.556 305.109 8,069.509
202309 8,986.781 307.789 9,750.685
202312 8,824.841 306.746 9,607.536
202403 9,196.857 312.332 9,833.475
202406 11,689.361 314.175 12,425.195
202409 11,755.304 315.301 12,450.665
202412 13,768.364 315.605 14,568.757
202503 13,613.762 319.799 14,216.252
202506 16,370.164 322.561 16,948.264
202509 18,782.929 324.800 19,312.182
202512 19,075.479 324.054 19,658.126
202603 19,592.199 330.213 19,814.041
202606 23,161.440 333.952 23,161.440

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Eli Lilly and Co (XSGO:LLYCL) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CLP1,104,400.00 is trading 23.3% below its estimated GF Value™ of CLP1,439,146.26. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSGO:LLYCL:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: CLP1,439,146.26 vs. price of CLP1,104,400.00 (23.3% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the XSGO:LLYCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
73GF Score

Get the complete analysis for XSGO:LLYCL

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CLP1,104,400.00
Price
CLP1,439,146.26
GF Value